NEW YORK (GenomeWeb) – Cancer diagnostics firm Pillar Biosciences has partnered with Illumina to develop next-generation sequencing-based in vitro diagnostics, the companies announced today.

Under the terms of the deal, Pillar will use its stem loop inhibition-mediated amplification (SLIMamp) technology — which is designed for amplifying overlapping or tiled amplicons in a single multiplex PCR reaction — to develop diagnostics that run on Illumina's MiSeqDx instrument.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.